T-DM1 meets OS endpoint

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said T-DM1 met the co-primary endpoint of improving overall survival vs. Tykerb lapatinib plus

Read the full 226 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE